China Pharma's Q4 Catalyst: Broker Reveals Top Picks Before Earnings Blowout

Very Bullish

What Happened

Huayuan Pharma released a note recommending CXO stocks with strong fundamentals ahead of Q3 earnings and advising active positioning in innovative drugs for Q4.

Bottom Line

Broker sentiment is bullish on China's CXO and innovative drug sectors, with specific stock picks poised for upside.

Free preview — more China A-share & HK research · About Us · Legal & Privacy